top of page

LEON M SMITH II

ELECT

Leon Smith-purple blazer1a.jpg

​Key Leadership Experiences & Noteworthy Accomplishments

I. Proven Track Record of Leadership for The Omicron Chi “Mighty OX” Chapter

Basileus

  • Served three terms (2015-18)

  • Implemented a 5-year strategic plan

  • 2-time International Large Chapter of Year (2015-16 & 2017-18)

  • 3-time Second District Large Chapter of the Year (2015-18)

  • 3-time 2nd Place Second District Social Action Large Chapter of the Year (2015-18)

  • Increase chapter membership by 96%

  • Hosted historic 2016 James S. Avery, Sr. Shirtsleeve Conference

  • Hosted 2018 International Candidates Forum for Second District

  • 87% retention of newly initiated brothers (financial and highly engaged after 3 years)

Vice Basileus

  • Served two terms (2013-15)

  • Supported and guided chapter committee chairs, fostering strong brotherhood engagement and

  • achieved exceptional results

  • Chapter awarded 2015 White House Service and White House Community Service Awards from

  • President Barack Obama

  • International Small Graduate Chapter of the Year (2014-15)

  • Second District Small Graduate Chapter of the Year (2014-15)

  • Second District Social Action Small Graduate Chapter of the Year (2014-15)

  • Led formal chapter meetings and officiated Memorial Services when called upon by the Basileus

Chaplain

  • Served two terms (2011-13)

  • Created and implemented the “To Artina Initiative” for visitation and engagement of our OX widows

  • Implemented a robust, multi-faceted annual Memorial Service Weekend

II. Transformation Leadership for Corridor IV  Corridor IV Representative 

  • Supported the vision and strategic imperatives of two Second District Representatives (2020-present)

  • Led Corridor during covid-19 pandemic and post-pandemic phases 

  • Revolutionized Corridor MSP program leading to unprecedented outcomes for new brothers and high  participation and engagement levels from brotherhood 

  • Team approach has led unprecedented corridor unity (North, South, and Central NJ)

  • Lead efforts to reactivate or maintain good standing of 11 of 12 undergraduate chapters by Spring 2024

  • Oversaw two the chartering of two chapters (Kappa Nu Nu & Alpha Epsilon Zeta) 

III. Exceptional Leadership at the Second District Level

  • Second District Achievement Week Committee (Chairman, 2018-20)

  • Second District STEM Committee (co-Chairman), 2023-present)

 IV. Beta Psi 1923 Foundation 

  • Founding Director (2016) 

  • Vice Chairman (Marketing, 2018-present) 

  • Since 2018, the foundation has contributed >$400,000 to Clark Atlanta  University including >$250,000 towards the Dr. Moses C. Norman, Sr.  Endowment Fund 

  • Embarking a one million dollar pledge to CAU over the next 10 years

Recognitions/Acknowledgements 

  • 2021 Second District Founders Lifetime Achievement Week Award

  • 2021 Second District Corridor Representative of the Year

  • 2021 Omicron Chi Founders Lifetime Achievement Week Award

  • 2021 Bishop A. Love Prayer Breakfast Honoree 

  • 2020 Second District Committee Chairman of the Year 

  • 2018 Psi Lambda Lambda Chapter “Trailblazer Award” 

  • 2017 Second District Basileus of the Year 

  • 2016 Delta Sigma Theta Sorority, Inc. EMBODI Award (Central  Jersey Alumnae) 

  • 2012 Omicron Chi Omega Man of the Year 

  • Life Member #6331

VI. Professional Accomplishments 

  • Professionally, he is an accomplished medicinal chemist with 25 years of experience in drug discovery across areas like CNS, metabolic diseases, oncology, and cardiovascular disease, at top pharmaceutical firms. 

  • research efforts have resulted in over 50 patents and peer-reviewed publications 

  • co-inventor of multiple small molecules that have progressed into human Phase I-III clinical studies including a current Phase III clinical candidate Milvexian, (BMS-986177/JNJ-70033093); BMS-962212, (Factor XIa, discontinued after Phase I), and Amgen’s first internally developed small molecule to undergo clinical evaluation (AMG706, discontinued after Phase III).

bottom of page